LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
WARREN, N.J., March 27, 2017 -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced a poster presentation at the 37th Annual Meeting for the International Society for Heart and Lung Transplantation (ISHLT) which will take place in San Diego, CA, from April 5 to 8. The poster will feature data from an investigator-led study of INOpulse® in patients with pulmonary arterial hypertension (PAH).
| Title: | Effects of Ambulatory Inhaled Nitric Oxide on Exercise Induced Increases in Pulmonary Pressures | |
| Authors: | R. A. Davey (Division of Cardiology, Western University, London, ON), A. Raina, R. L. Benza (Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA) | |
| Date: | Thursday, April 6 | |
| Time: | 6:15 – 7:15 pm Pacific Time | |
| Session: | Poster Session 2 | |
Pulmonary arterial hypertension (PAH) is characterized by progressive increases in pulmonary vascular resistance (PVR) and subsequent reductions in cardiac output; these changes are further worsened by exercise. Inhaled nitric oxide (iNO) can decrease PVR and improve cardiac output in PAH patients.
In this study, the investigators looked at the effects of pulsed iNO on PVR and cardiac output in PAH patients with the CardioMEMS, an implantable hemodynamic monitoring device, both before and after exercise. Inhaled NO was delivered using Bellerophon’s proprietary INOpulse delivery system, that provides pulsed iNO in the ambulatory setting. The INOpulse delivery system is designed to be used chronically in outpatients and is currently in Phase 3 clinical trials for PAH.
About ISHLT
The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy. ISHLT was founded in 1981 and today has more than 3,400 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. The 37th Annual Meeting and Scientific Sessions will take place at the Manchester Grand Hyatt, San Diego, April 5 – 8. For more information, refer to http://www.ishlt.org/meetings/annualMeeting.asp.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF), both of which are in Phase 2 development. For more information, please visit www.bellerophon.com.
Contacts At Bellerophon: Fabian Tenenbaum, Chief Executive Officer (908) 574-4767 At LifeSci Advisors: Bob Yedid (646) 597-6989 [email protected]
